Atlas Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Clinical trial NCT04392648 · WITHDRAWN

Trial details

NCT number
NCT04392648
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed and/or Refractory Multiple Myeloma
Start date
2020-06-24
Primary completion
2023-11-10
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.